KDR and neoplasm: The most active derivative 39, which was a FLT3/VEGFR2 dual inhibitor, showed strong anticancer activity (by suppressing cell growth) toward A549 and HT-29 tumor cell lines with an IC50 value of 0.65 μM and 0.11 μM, respectively.